Collectively these data imply that tumor resistance to doxorubicin mediated by MCL1 nuclear translocation can be overcome by treatment with small molecule inhibitors of Bcl-xL, A-1331852, but this mechanism is dependent upon ENO1. Here, MCL1 is linked to neoplasm.